[go: up one dir, main page]

MX2014003153A - Prediccion de riesgo de evento cardiovascular y usos del mismo. - Google Patents

Prediccion de riesgo de evento cardiovascular y usos del mismo.

Info

Publication number
MX2014003153A
MX2014003153A MX2014003153A MX2014003153A MX2014003153A MX 2014003153 A MX2014003153 A MX 2014003153A MX 2014003153 A MX2014003153 A MX 2014003153A MX 2014003153 A MX2014003153 A MX 2014003153A MX 2014003153 A MX2014003153 A MX 2014003153A
Authority
MX
Mexico
Prior art keywords
cardiovascular risk
risk event
biomarkers
event prediction
years
Prior art date
Application number
MX2014003153A
Other languages
English (en)
Other versions
MX373248B (es
Inventor
Rosalynn Dianne Gill
Stephen Alaric Williams
Alex A E Stewart
Robert Mehler
Trudi Foreman
Britta Singer
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of MX2014003153A publication Critical patent/MX2014003153A/es
Publication of MX373248B publication Critical patent/MX373248B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Se describen biomarcadores, métodos, dispositivos, reactivos, sistemas y kits para la evaluación de riesgo de un evento cardiovascular (CV) dentro de 5 años. Los biomarcadores que pueden ser utilizados solos o en diversas combinaciones para evaluar el riesgo de un evento CV dentro de 5 años. Los métodos se proporcionan para evaluar el riesgo de un evento CV dentro de 5 años en un individuo, en donde los métodos incluyen detectar, en una muestra biológica de un individuo, por lo menos un valor de biomarcador, el biomarcador se selecciona de un grupo de biomarcadores.
MX2014003153A 2011-09-30 2012-09-28 Prediccion de riesgo de evento cardiovascular y usos del mismo. MX373248B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541828P 2011-09-30 2011-09-30
PCT/US2012/058060 WO2013049674A1 (en) 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof

Publications (2)

Publication Number Publication Date
MX2014003153A true MX2014003153A (es) 2014-04-30
MX373248B MX373248B (es) 2020-05-11

Family

ID=47993164

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014003153A MX373248B (es) 2011-09-30 2012-09-28 Prediccion de riesgo de evento cardiovascular y usos del mismo.
MX2020004617A MX2020004617A (es) 2011-09-30 2014-03-14 Prediccion de riesgo de evento cardiovascular y usos del mismo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020004617A MX2020004617A (es) 2011-09-30 2014-03-14 Prediccion de riesgo de evento cardiovascular y usos del mismo.

Country Status (16)

Country Link
US (3) US20130085079A1 (es)
EP (1) EP2761289B1 (es)
JP (3) JP6652781B2 (es)
KR (2) KR102248900B1 (es)
CN (4) CN103959060B (es)
AU (1) AU2013202112B9 (es)
BR (2) BR112014007214B1 (es)
CA (2) CA2847903C (es)
ES (1) ES2777002T3 (es)
IL (1) IL231387A (es)
IN (1) IN2014CN01970A (es)
MX (2) MX373248B (es)
RU (1) RU2651708C2 (es)
SG (3) SG10201906900QA (es)
WO (1) WO2013049674A1 (es)
ZA (1) ZA201401778B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
WO2011154689A1 (en) * 2010-06-07 2011-12-15 King's College London Methods and means for predicting or diagnosing diabetes or cardiovascular disorders based on micro rna detection
KR101870123B1 (ko) 2010-07-09 2018-06-25 소마로직, 인크. 폐암 바이오마커 및 그것의 용도
CA2804857C (en) 2010-08-13 2021-07-06 Somalogic, Inc. Pancreatic cancer biomarkers and uses thereof
EP2683729B1 (en) 2011-03-10 2017-05-03 Somalogic, Inc. Aptamers for clostridium difficile diagnostics
CN103959060B (zh) * 2011-09-30 2017-05-17 私募蛋白质体公司 心血管危险事件预测及其用途
SG11201505515XA (en) 2012-01-27 2015-09-29 Univ Leland Stanford Junior Methods for profiling and quantitating cell-free rna
JP6198047B2 (ja) * 2013-08-02 2017-09-20 国立大学法人岐阜大学 冠動脈疾患の検査キット
BR112016005957A2 (pt) 2013-09-24 2017-09-26 Somalogic Inc detecção de alvo multiaptâmero
CN107076755B (zh) * 2014-03-21 2019-03-29 赛诺菲-安万特德国有限公司 用于评估心血管病症进展风险的新标志物
CA2949731A1 (en) * 2014-06-05 2015-12-10 Sanofi-Aventis Deutschland Gmbh New markers for the assessment of an increased risk for mortality
BR112017005730B1 (pt) * 2014-09-26 2023-12-12 Somalogic Operating Co., Inc Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
AU2016291558A1 (en) * 2015-07-10 2018-02-08 West Virginia University Markers of stroke and stroke severity
RU2602451C1 (ru) * 2015-08-28 2016-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого" Министерства здравоохранения Российской Федерации Способ диагностики генетической предрасположенности к развитию ишемического инсульта у больных с фибрилляцией предсердий
MX2018009170A (es) * 2016-02-08 2018-11-19 Somalogic Inc Biomarcadores de la enfermedad del higado graso no alcoholico (nafld) y esteatohepatitis no alcoholica (nash) y usos de estos.
US20190071795A1 (en) * 2016-03-09 2019-03-07 Molecular Stethoscope, Inc. Methods and systems for detecting tissue conditions
JP2019516095A (ja) * 2016-04-06 2019-06-13 ネステク ソシエテ アノニム 減量の程度を予測するためのバイオマーカー
JP6721155B2 (ja) 2016-04-15 2020-07-08 オムロン株式会社 生体情報分析装置、システム、及び、プログラム
CN105907857A (zh) * 2016-04-29 2016-08-31 天津脉络生物科技有限公司 一种用于动脉血栓的分子标记物和试剂及其应用
WO2017214684A1 (en) * 2016-06-17 2017-12-21 Adelaide Research & Innovation Pty Ltd Methods and products for identifying conditions associated with cardiac fibrotic remodelling
ES2817087T3 (es) * 2016-08-04 2021-04-06 Hoffmann La Roche ESM-1 (endocan) circulante en la evaluación de la fibrilación auricular
US11079394B2 (en) * 2017-07-25 2021-08-03 Vanderbilt University Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure
JP7058331B2 (ja) * 2017-12-13 2022-04-21 エフ．ホフマン－ラ ロシュ アーゲー 脳卒中の予測のための循環アンジオポエチン－２（Ａｎｇ－２）およびインスリン様増殖因子結合タンパク質７（ＩＧＦＢＰ７）
RU2685859C1 (ru) * 2018-07-04 2019-04-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ прогнозирования риска развития ишемического инсульта
CN109192250B (zh) * 2018-08-01 2021-12-07 华东理工大学 一种多相催化中克服表面物种快速迁移的加速模拟方法
JP7389108B2 (ja) * 2018-08-10 2023-11-29 エフ． ホフマン－ラ ロシュ アーゲー 心房細動関連脳卒中の評価のためのｃｅｓ－２（カルボキシルエステラーゼ－２）
WO2020037244A1 (en) * 2018-08-17 2020-02-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Use of machine learning models for prediction of clinical outcomes
EP3841381A1 (en) * 2018-08-22 2021-06-30 Roche Diagnostics GmbH Circulating spon-1 (spondin-1) in the assessment of atrial fibrillation
BR112021008262A2 (pt) * 2018-10-31 2021-10-26 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Biomarcadores de aterosclerose subclínica
KR102125053B1 (ko) * 2018-12-14 2020-06-19 가톨릭대학교 산학협력단 심혈관계 질환의 검출용 조성물 및 이를 포함하는 키트
SG11202108405VA (en) 2019-02-14 2021-08-30 Mirvie Inc Methods and systems for determining a pregnancy-related state of a subject
GB201906052D0 (en) 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity
US11030743B2 (en) * 2019-05-16 2021-06-08 Tencent America LLC System and method for coronary calcium deposits detection and labeling
JP7712913B2 (ja) * 2019-09-03 2025-07-24 ソマロジック オペレーティング カンパニー インコーポレイテッド 心血管リスク／イベントの予測及びその使用
JP7510649B2 (ja) * 2019-11-06 2024-07-04 国立大学法人 香川大学 心不全マーカー
US10902955B1 (en) 2020-05-01 2021-01-26 Georgetown University Detecting COVID-19 using surrogates
CA3179456A1 (en) * 2020-05-19 2021-11-25 Henricus J. DUCKERS Detection and treatment of conditions characterized by perfusion shortage
FI130424B (en) * 2020-06-18 2023-08-23 Nightingale Health Oy Procedure for determining whether a subject has a disease or condition or whether the subject is at risk of developing a disease or condition
BR112023004855A2 (pt) * 2020-10-20 2023-05-02 Somalogic Operating Co Inc Predição de risco de evento cardiovascular
RU2750716C1 (ru) * 2020-11-23 2021-07-01 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ прогнозирования сердечно-сосудистых осложнений у больных низкого или умеренного сердечно-сосудистого риска путем оценки их психологического статуса
US20240060998A1 (en) * 2021-02-01 2024-02-22 Medtronic, Inc. A method to identify lvad patients with elevated levels of blood activation using coupon tests
RU2757752C1 (ru) * 2021-04-26 2021-10-21 Общество с ограниченной ответственностью "Медицинская Технологическая Компания" (ООО МТК) Способ определения индивидуального профиля факторов суммарного сердечно-сосудистого риска у пациента трудоспособного возраста
WO2023023748A1 (en) * 2021-08-26 2023-03-02 3P Healthcare Pty Ltd System and method for cardiovascular health assessment and risk management
US12412661B2 (en) 2021-11-25 2025-09-09 Samsung Electronics Co., Ltd. Electronic device and method of providing health guideline using the same
EP4230233A1 (en) * 2022-02-22 2023-08-23 mimiX Biotherapeutics Sàrl Method for producing tissue constructs
WO2023201054A1 (en) * 2022-04-15 2023-10-19 Memorial Sloan-Kettering Cancer Center Multi-modal machine learning to determine risk stratification
CN115932276B (zh) * 2022-12-07 2025-09-02 首都医科大学附属北京安贞医院 一种检测生物标志物的产品在制备急性心肌梗死或其并发症的诊断的产品中用途
WO2024226519A2 (en) * 2023-04-24 2024-10-31 Google Llc Deep learning-based photoplethysmography model for cardiovascular risk prediction

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
JP2004500100A (ja) * 2000-03-06 2004-01-08 スミスクライン・ビーチャム・コーポレイション 新規化合物
US20030224501A1 (en) * 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
CN1668763B (zh) * 2002-05-09 2012-05-16 布赖汉姆妇女医院 作为心血管病的标志和治疗靶的il1rl-1
WO2005005601A2 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
JP2008523394A (ja) * 2004-12-10 2008-07-03 ユニヴァーシティー オブ メリーランド， バルティモア 炎症及び肥満症における血清アミロイドａタンパク質
CN2783324Y (zh) * 2005-04-28 2006-05-24 穆海东 心血管疾病诊断和预测多指标蛋白芯片检测试剂盒
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
WO2007086980A2 (en) * 2005-11-10 2007-08-02 Duke University Methods of determining the risk of developing coronary artery disease
AU2007210643B2 (en) * 2006-01-31 2013-09-19 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for determination of condition of disseminated intravascular coagulation syndrome
EP2005168A4 (en) * 2006-03-09 2009-05-20 Biosite Inc METHODS AND COMPOSITIONS FOR DIAGNOSING DISEASES OF AORTA
CA2659082A1 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
EP1887361A1 (en) * 2006-08-07 2008-02-13 Bio-Rad Pasteur Method for the prediction of vascular events
US7947447B2 (en) * 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
RU2376372C2 (ru) * 2007-04-03 2009-12-20 Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук Способ генетической диагностики подверженности к сердечно-сосудистым заболеваниям
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
DK2182981T3 (en) * 2007-08-02 2013-04-02 Gilead Biologics Inc Methods and compositions for treatment and diagnosis of fibrosis.
GB0717637D0 (en) * 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
WO2009075566A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
WO2009091581A2 (en) * 2008-01-18 2009-07-23 Vatrix Medical, Inc. Diagnostic biomarkers for vascular aneurysm
US8030097B2 (en) * 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
CN102186483A (zh) * 2008-08-11 2011-09-14 德克萨斯大学系统董事会 促进血管完整性的微rna及其用途
WO2010040564A1 (en) * 2008-10-07 2010-04-15 B.R.A.H.M.S. Ag Biomarker for the prediction of first adverse events
US8450069B2 (en) * 2009-06-08 2013-05-28 Singulex, Inc. Highly sensitive biomarker panels
EP2264183B1 (en) * 2009-06-09 2016-12-07 Gendiag.exe, S.L. Risk markers for cardiovascular disease
BRPI1010693A2 (pt) * 2009-06-15 2019-07-16 Cardiodx Inc métodos implementados por computador para marcar e/ou pontuar uma primeira amostra obtida a partir de um sujeito, meios de armazenamento legível em computador de armazenamento de código de programa executável e métodos, sistema e kits de predição de cad em um sujeito
EP2494364A1 (en) * 2009-10-29 2012-09-05 Tethys Bioscience, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
US20110144914A1 (en) * 2009-12-09 2011-06-16 Doug Harrington Biomarker assay for diagnosis and classification of cardiovascular disease
EP2542266A4 (en) * 2010-03-03 2013-10-23 Somalogic Inc 4-1BB-BINDING APTAMERS AND USE THEREOF IN THE TREATMENT OF DISEASES AND DISORDERS
CN103959060B (zh) * 2011-09-30 2017-05-17 私募蛋白质体公司 心血管危险事件预测及其用途
ES2779698T3 (es) * 2012-03-19 2020-08-18 Brigham & Womens Hospital Inc Factor 11 de diferenciación del crecimiento (GDF) para el tratamiento de afecciones cardiovasculares relacionadas con la edad

Also Published As

Publication number Publication date
IL231387A (en) 2017-12-31
CN103959060B (zh) 2017-05-17
BR122019023720A2 (es) 2017-04-04
HK1247666A1 (zh) 2018-09-28
US20130085079A1 (en) 2013-04-04
SG11201400904SA (en) 2014-04-28
NZ622118A (en) 2016-01-29
AU2013202112B2 (en) 2015-09-24
EP2761289B1 (en) 2020-02-12
RU2014110508A (ru) 2015-11-10
AU2013202112B9 (en) 2015-10-22
CN107102151A (zh) 2017-08-29
IN2014CN01970A (es) 2015-05-29
JP2014528576A (ja) 2014-10-27
CA2847903A1 (en) 2013-04-04
CN107422126B (zh) 2020-03-27
CA3074279C (en) 2021-10-19
SG10201607331WA (en) 2016-11-29
BR112014007214B1 (pt) 2022-08-16
BR112014007214A2 (pt) 2017-04-04
KR102111624B1 (ko) 2020-05-18
IL231387A0 (en) 2014-04-30
CN103959060A (zh) 2014-07-30
WO2013049674A1 (en) 2013-04-04
KR102248900B1 (ko) 2021-05-07
MX2020004617A (es) 2020-08-06
MX373248B (es) 2020-05-11
BR122019023720B1 (pt) 2023-01-24
CN114518458A (zh) 2022-05-20
EP2761289A1 (en) 2014-08-06
CA2847903C (en) 2020-10-27
SG10201906900QA (en) 2019-09-27
ZA201401778B (en) 2018-08-25
KR20200055804A (ko) 2020-05-21
ES2777002T3 (es) 2020-08-03
JP6917432B2 (ja) 2021-08-11
JP6546318B2 (ja) 2019-07-17
KR20140084106A (ko) 2014-07-04
BR112014007214A8 (pt) 2022-07-26
JP2018159713A (ja) 2018-10-11
EP2761289A4 (en) 2015-08-12
JP6652781B2 (ja) 2020-02-26
US20200166523A1 (en) 2020-05-28
US20150168423A1 (en) 2015-06-18
JP2020024216A (ja) 2020-02-13
BR122019023720A8 (pt) 2022-07-26
AU2013202112A1 (en) 2013-05-02
CN107422126A (zh) 2017-12-01
CA3074279A1 (en) 2013-04-04
RU2651708C2 (ru) 2018-04-23

Similar Documents

Publication Publication Date Title
MX2014003153A (es) Prediccion de riesgo de evento cardiovascular y usos del mismo.
BR112013003391A2 (pt) biomarcadores de câncer pancreático e usos dos mesmos
BR112016008970A2 (pt) Método de ativação ex vivo e para avaliar ativação plasmática em um indivíduo, ensaio ex vivo para determinar atividade de calicreína plasmática em uma amostra
WO2014186761A3 (en) Methods for determining responsiveness to an anti-cd47 agent
GB2556004A (en) Markers of stroke and stroke severity
BR112014006432A2 (pt) biomarcadores do câncer de pulmão e seus usos
EP4249605A3 (en) Methods for analyte detection
MY170164A (en) Aptamer-based multiplexed assays
BR112012011230A2 (pt) fatores de risco e previsão de infarto do miocárdio
MX392706B (es) Ensayo a base de células para detectar homodímeros anti-cd3.
MY198081A (en) Urinalysis device and dry reagent for quantitative urinalysis
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
WO2016198833A3 (en) Methods for analysing a urine sample
BR112016010106A2 (pt) ensaios para igfbp7 com melhor desempenho em amostras biológicas
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
MX2019001134A (es) Sistemas y metodos para la deteccion de reacciones quimioluminiscentes.
MX2015013596A (es) Metodos, dispositivos y sistemas para analisis de muestras.
CO6311041A2 (es) Un metodo para determinar y monitorear un cancer ginecologico que comprende la determinacion de niveles de biomarcadores en una muestra biologica
MX2017001134A (es) Composiciones y metodos para la deteccion y analisis de tuberculosis micobacteriana.
MX2019000591A (es) Tira mejorada de ensayo de analisis de orina de bajo volumen de muestra, kits analiticos y metodos de uso relacionados con la misma.
NZ601648A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3557259A3 (en) Methods and arrays for use in the same
BR112018075223A2 (pt) assinaturas de biomarcador de lúpus eritematoso sistêmico e usos das mesmas
BR112012024175A2 (pt) hbf e a1m como marcadores de estágio precoce para preeclampsia
NZ605561A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
FG Grant or registration